Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 466

Sort by

Sort Order Select

Journal Articles

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

Yin Yuan, Stephen Boyle

Blood (2021) 137 (23): 3310.

https://doi.org/10.1182/blood.2021011357

Published: 2021

Journal Articles

Plasmablastic Lymphoma in a Community-Based Cancer Center: A 10-Year Analysis of This Rare Disease in a Underserved Urban Area

Vinicius Machado Jorge, MD, Andrew Tiu, MD, Sorab Gupta, MD, Claudia Dourado, MD, Gabor Varadi, MD

Blood (2019) 134 (Supplement_1): 5361.

https://doi.org/10.1182/blood-2019-131905

Published: 2019

Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 5243.

https://doi.org/10.1182/blood-2019-122759

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Early Mortality after Diagnosis of Diffuse Large B-Cell Lymphoma : A Retrospective, Single Urban-Community Hospital Study

Kunhwa Kim, MDMPH, Vinicius Machado Jorge, MD, Andrew Tiu, MD, Peter Mousaa, Sorab Gupta, MD, Djeneba Djibo, Claudia Dourado, MD

Blood (2019) 134 (Supplement_1): 5335.

https://doi.org/10.1182/blood-2019-132126

Published: 2019

Journal Articles

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Anja Feldmann, PhD, Stefanie Koristka, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Anja Hoffmann, Justyna Jureczek, Nicola Mitwasi, Martin Bornhaeuser, MD, Václav Hořejší, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5612.

https://doi.org/10.1182/blood-2019-128193

Published: 2019

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Sameem Abedin, MD, Guru Subramanian Guru Murthy, MBBS, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Alexandra M. Harrington, MDMT(ASCP), Karen Carlson, MD

Blood (2019) 134 (Supplement_1): 2605.

https://doi.org/10.1182/blood-2019-122487

Published: 2019

Journal Articles

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MDMSc, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro N. Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2637.

https://doi.org/10.1182/blood-2019-127803

Published: 2019

Journal Articles

Intensive Chemotherapy Along with Aggressive Supportive Care Can Spare Stem Cell Transplantation in a Subset of Patients without Compromising an Outcome in Infants with Acute Lymphoblastic Leukemia; A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL-10

Blood (2019) 134 (Supplement_1): 2626.

https://doi.org/10.1182/blood-2019-121328

Published: 2019

Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD

Blood (2019) 134 (Supplement_1): 2649.

https://doi.org/10.1182/blood-2019-129805

Published: 2019

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

A Retrospective Review of Mercaptopurine Metabolism Reveals High Rate of Patients with Suboptimal Metabolites Successfully Corrected with Allopurinol

Lauren Marie Vasta, MD, Richard C Zanetti, MD, Dina S. Parekh, MD, Anne B. Warwick, MD MPH, Kenneth Lieuw, MD PhD

Blood (2019) 134 (Supplement_1): 3878.

https://doi.org/10.1182/blood-2019-126184

Published: 2019

Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH

Blood (2019) 134 (Supplement_1): 3910.

https://doi.org/10.1182/blood-2019-127416

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

Plasmablastic Lymphoma in a Community-Based Cancer Center: A 10-Year Analysis of This Rare Disease in a Underserved Urban Area

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Early Mortality after Diagnosis of Diffuse Large B-Cell Lymphoma : A Retrospective, Single Urban-Community Hospital Study

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Intensive Chemotherapy Along with Aggressive Supportive Care Can Spare Stem Cell Transplantation in a Subset of Patients without Compromising an Outcome in Infants with Acute Lymphoblastic Leukemia; A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL-10

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

A Retrospective Review of Mercaptopurine Metabolism Reveals High Rate of Patients with Suboptimal Metabolites Successfully Corrected with Allopurinol

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only